Dermatology · PANCE / PANRE

Hidradenitis Suppurativa

Chronic recurrent follicular occlusive disease of intertriginous areas with painful nodules, abscesses, sinus tracts, and scarring.

Also known as: hidradenitis suppurativa, HS, acne inversa, Verneuil disease

Overview

A chronic, recurrent, inflammatory follicular occlusive disorder presenting with painful deep-seated nodules, abscesses, sinus tracts, and dermal scarring in intertriginous areas (axillae, inguinal, gluteal, inframammary, perianal).

Epidemiology

Prevalence ~1% (likely underestimated; often misdiagnosed for years). Female predominance 3:1. Onset typically after puberty, peak ages 20-40. Higher prevalence in African American populations and patients with obesity, smoking, and metabolic syndrome.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Hidradenitis Suppurativa outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Smoking (90% of patients are current or former smokers) — strongest modifiable risk factor
  • Obesity (mechanical friction, hormonal milieu)
  • Family history (~30%) — autosomal dominant with variable penetrance in some kindreds (γ-secretase mutations)
  • Female sex; menstruation may worsen flares
  • Metabolic syndrome, type 2 diabetes, PCOS
  • Acne, inflammatory bowel disease (Crohn > UC), spondyloarthropathy associations

Pathophysiology

Follicular hyperkeratinization and dilatation in apocrine gland-bearing skin → follicular occlusion → rupture into dermis → robust neutrophilic inflammation, sinus tract formation, and scarring. NOT a primary apocrine gland disease (older name 'apocrinitis' is incorrect). TNF-α, IL-17, IL-1β drive inflammation; γ-secretase / Notch pathway implicated in familial forms.

Clinical presentation

Symptoms

  • Painful recurrent nodules and abscesses, often draining purulent foul-smelling discharge
  • Pruritus, burning, stinging
  • Sleep disturbance, dyspareunia, gait disturbance, work absences
  • Significant pain — worst-rated chronic dermatologic disease in quality of life surveys

Signs / physical exam

  • Primary lesions: tender, deep-seated, dermal/subcutaneous inflammatory nodules and abscesses
  • Secondary lesions: open comedones (double-headed 'tombstone' comedones — pathognomonic), sinus tracts (interconnecting tunnels), hypertrophic and atrophic scars, contractures, lymphedema
  • Distribution: axillae (most common), inguinal folds, perianal/perineal, buttocks, inframammary, submammary; less commonly nape, retroauricular, scalp
  • Lesions tend to be bilateral and symmetric
  • Hurley staging (clinical):
  • • I: solitary or multiple abscesses, NO sinus tracts or scarring
  • • II: recurrent abscesses with sinus tracts and scarring, separated by normal skin
  • • III: diffuse or near-diffuse involvement, multiple interconnected sinus tracts and abscesses across entire area

Classic findings

Recurrent abscesses + sinus tracts + bridged scarring in axillae and groin; double-comedones.

Differential diagnosis

  • Cutaneous abscess / furunculosis — Single acute abscess, not recurrent in same site, no sinus tracts; staphylococcal
  • Cystic acne / acne conglobata — Comedones present (HS lacks except 'double comedones'), trunk/face distribution
  • Crohn disease (metastatic / fistulating) — Perianal fistulas + GI symptoms; can overlap with HS
  • Pilonidal disease — Sacrococcygeal area, with hair tuft; not symmetric or multifocal
  • Granuloma inguinale (donovanosis) — Genital ulcers, slow growth, geographic exposure; Donovan bodies on smear
  • Lymphogranuloma venereum — Groove sign with bubo formation; serotype L1-L3 chlamydia
  • Steatocystoma multiplex — Multiple small cysts on chest/axillae, no inflammation or sinus tracts
  • Actinomycosis — Chronic sinus tracts with 'sulfur granules'; Actinomyces israelii

Diagnostic workup

Diagnostic criteria

All three required (Dessau criteria): (1) typical lesions (nodules, abscesses, sinus tracts, scars), (2) typical locations (intertriginous), (3) chronic relapsing course.

Labs

  • Clinical diagnosis — no required labs
  • CBC, CRP, ESR (elevated during flares)
  • Bacterial culture if secondary infection or atypical presentation (cultures often polymicrobial or sterile; routine antibiotics target empirically)
  • Screen comorbidities: metabolic syndrome (lipid panel, HbA1c), depression
  • Skin biopsy in atypical cases; rule out Crohn-related disease

Imaging

  • Ultrasound (high-frequency) — assesses sinus tract extent, often used to plan surgery
  • MRI for complex perineal/perianal disease and Crohn overlap
  • Sinography in selected presurgical cases

Diagnostic algorithm

Hurley StageClinical FeaturesPreferred Therapy
I (mild)Solitary/multiple abscesses; NO sinus tracts/scarringTopical clindamycin; doxycycline; antiseptic washes; lifestyle
II (moderate)Recurrent abscesses + sinus tracts/scars, separated by normal skinClindamycin + rifampin; adalimumab/secukinumab; localized excision/deroofing
III (severe)Diffuse interconnected sinus tracts and abscessesBiologic therapy + wide local excision; multidisciplinary care
Hurley staging of hidradenitis suppurativa and preferred therapy.

Treatment

First-line

  • Lifestyle: smoking cessation (most impactful intervention), weight reduction, loose breathable clothing, avoid friction/shaving
  • Daily antiseptic wash: chlorhexidine 4%, dilute bleach baths, benzoyl peroxide 5-10%
  • Topical clindamycin 1% solution BID for mild Hurley I disease
  • Hurley I-II: oral tetracycline antibiotic — doxycycline 100 mg BID × 12 weeks (anti-inflammatory dose) OR minocycline
  • Hurley II refractory or moderate-severe: combination oral clindamycin 300 mg BID + rifampin 300 mg BID × 10-12 weeks
  • Biologic therapy (Hurley II-III or refractory): adalimumab 160 mg loading → 80 mg week 2 → 40 mg weekly (FDA-approved); secukinumab (FDA-approved 2023); bimekizumab (recent approval)
  • Hormonal therapy in women: combined oral contraceptive (anti-androgenic — drospirenone/EE), spironolactone 50-200 mg/day, metformin
  • Intralesional triamcinolone 5-10 mg/mL for individual acute nodules
  • Pain control: acetaminophen, NSAIDs, gabapentin/pregabalin for neuropathic component; avoid chronic opioids

Severe Hurley III / extensive sinus disease

  • Wide local excision of involved areas with secondary intention healing or split-thickness grafting — definitive for Hurley III in affected region
  • Deroofing of sinus tracts (preferred over excision when possible)
  • Combine with biologic therapy preoperatively to reduce inflammation
  • Multidisciplinary care: dermatology, plastic surgery, pain, mental health

Acute abscess

  • Incision and drainage for relief (recognize recurrence is the rule; not curative)
  • Intralesional triamcinolone immediately after I&D
  • Punch debridement of inflamed nodules

Second-line / adjunct

  • Oral retinoids: acitretin or isotretinoin (limited evidence for HS but used in some)
  • Dapsone, colchicine, zinc supplementation (limited evidence)
  • Cyclosporine, methotrexate for refractory cases
  • JAK inhibitors (upadacitinib) — emerging data
  • Laser hair removal (Nd:YAG) reduces follicular occlusion in affected sites

Complications

  • Severe pain, depression, suicidality (rates exceed other chronic dermatoses)
  • Sexual dysfunction, infertility (genital scarring)
  • Lymphatic obstruction, lymphedema
  • Fistulas to urethra, bladder, rectum
  • Cutaneous squamous cell carcinoma in long-standing perianal/buttock disease (~3% lifetime, often aggressive)
  • Anemia of chronic disease, hypoproteinemia
  • Cardiovascular disease (independent risk factor), metabolic syndrome

PANCE pearls

  • Recurrent painful boils in the axillae or groin = HS until proven otherwise; not 'staph infections.'
  • Smoking cessation is the single most impactful lifestyle intervention — strongly counsel at every visit.
  • Double-headed open comedones in affected areas are pathognomonic.
  • Antibiotics work via anti-inflammatory mechanisms, not antimicrobial — failure to respond does not mean culture-directed therapy is needed.
  • Long-standing perineal/buttock HS carries a real risk of cutaneous SCC — biopsy any chronic non-healing lesion.

References

  • USCMS 2019 — North American Clinical Management Guidelines for Hidradenitis Suppurativa (Alikhan et al., J Am Acad Dermatol 2019)
  • EHSF 2019 — European S1 Guideline for the Treatment of Hidradenitis Suppurativa (Zouboulis et al., J Eur Acad Dermatol Venereol 2015; updates ongoing)
  • AAD 2024 — Joint AAD-HS Foundation Clinical Care Updates on Biologics and Surgical Options

Practice Dermatology questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.